Device for treating lung of patient

Abstract

The invention discloses a device for treating the lung of a patient. The device comprises a membrane component and a supporting and protecting component, wherein air in a target region is discharged and external gas containing oxygen is stopped from entering the target region by the membrane component; the supporting and protecting component is used for supporting and protecting the membrane component so that an oxygen-deficient environment is formed in the target region, and mycobacterium tuberculosis can die due to oxygen deficiency. The device is used for interventional therapy on lung diseases, particularly pulmonary tuberculosis; after the device is placed in the pulmonary tuberculosis target region, air circulation between the outside and a pulmonary tuberculosis target hole can be isolated, and then the mycobacterium tuberculosis can die due to oxygen deficiency. By the device, sputum bacteria in the pulmonary tuberculosis target hole can further be sucked through a delivering catheter or guide wire, and therefore, further dissemination of the mycobacterium tuberculosis is avoided. Drugs are delivered into the pulmonary tuberculosis target hole for therapy, the mycobacterium tuberculosis is killed, and therefore, effects of purifying the hole and promoting the mycobacterium tuberculosis to become negative and the hole to be closed are achieved.

Description

technical field [0001] The invention relates to a medical device, in particular to a device for treating a patient's lung in interventional therapy, especially a device for treating a patient's pulmonary tuberculosis, especially for multidrug-resistant tuberculosis. Background technique [0002] Tuberculosis is a respiratory infectious disease that seriously endangers human health. Since the invention of antibiotics, tuberculosis is no longer an untreatable white plague. As long as standardized treatment, 85% to 95% of tuberculosis patients can be cured. However, since the 1990s, there has been a global resurgence of tuberculosis in the world, and a bigger problem has emerged in tuberculosis—drug resistance. In particular, multidrug-resistant cavitary tuberculosis is increasing year by year, increasing the difficulty of prevention and control. Drug-resistant tuberculosis refers to the resistance of tuberculosis bacteria in tuberculosis patients to a first-line anti-tubercu...

AI Technical Summary

Problems solved by technology

There are following defects in the chemotherapy of multidrug-resistant cavitary tuberculosis patients by conventional routes of administration (oral, intramuscular injection, intravenous injection): 1. long treatment cycle: for an ordinary tuberculosis patient, the treatment cycle is generally 6 months; The treatment cycle for patients with cavitary tuberculosis is 18 to 24 months, or even 36 months, which is 3 to 6 times that of ordinary tuberculosis patients; as one of the most important second-line drugs, injections (such as kanamycin, capreomycin, etc.) at least 6 months

② There are many therapeutic drugs, and the incidence of adverse reactions is high: there are about 4 to 5 kinds of first-line drugs for the treatment of ordinary pulmonary tuberculosis patients, and the adverse reaction rate is not high; while the treatment of multidrug-resistant cavitary tuberculosis patients is at least 5 to 6 kinds of drugs, and the adverse reactions are Second-line anti-tuberculosis drugs with high rates, such as capreomycin, cycloserine, prothionamide, etc.

③Low cure rate: At present, the cure rate of ordinary tuberculosis patients is more than 85%, and it has exceeded 90% in my country; while the highest cure rate of multidrug-resistant cavitary tuberculosis patients is only about 50-60%. This means that under the existing conditions Half of patients with MDR-cavitary tuberculosis will remain uncured

④ Expensive drug costs: It is estimated that the total drug cost for a 6-month treatment of an ordinary tuberculosis patient in my country is about 600 yuan, while the total cost of a 24-month treatment drug for a multidrug-resistant cavitary tuberculosis patient is about 30,000 yuan

This method is currently mainly used clinically for cavities that are not suitable for fiberoptic bronchoscopy or cannot be reached by fiberoptic bronchoscopy, but there is still a risk of residual Mycobacterium tuberculosis, and there is a risk of puncture complications such as pneumothorax

Images